Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
✍ Scribed by Sabine Brüsselbach; Dirk M. Nettelbeck; Hans-Harald Sedlacek; Rolf Müller
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- French
- Weight
- 173 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The anti-tumor drug Flavopiridol is a potent inhibitor of cyclin-dependent kinases (cdks). As a consequence, Flavopiridol-treated cells arrest in both G1 and G2, but Flavopiridol has also been shown to be cytotoxic for some tumor cell lines. The underlying molecular events are, however, unclear. We now show that Flavopiridol induces apoptosis in human umbilical vein endothelial cells (HUVECs), as judged by the occurrence of classical apoptotic markers, including chromatin condensation, internucleosomal cleavage, DNA fragmentation (TUNEL assay), annexin V binding and poly(ADP-ribose) polymerase (PARP)-cleavage. Such induction of apoptosis occurs with equal efficiency in both proliferating and G0/G1-arrested cells. Because growth-arrested HUVECs lack cdk2 activity and contain high levels of the cdk inhibitor p27, our observations suggest that cell cycle regulated cdks may not be the only critical target for Flavopiridol-induced apoptosis. Surprisingly, A549 lung carcinoma cells were clearly dependent on cell proliferation for the induction of cell death, pointing to cell type-related differences in the mechanism of Flavopiridol action.
📜 SIMILAR VOLUMES
We determined the effect of the highly selective cyclooxygenase-2 (COX-2) inhibitor NS-398 on proliferation, apoptosis and COX-2 regulation in 3 pre-malignant human colorectal adenoma cell lines (RG/C2, AA/C1, RR/C1) and compared its effect on 3 colorectal carcinoma cell lines (HT29, KS, JW2). COX-2
## Abstract ## Objective To determine whether treatment with the chimeric anti–tumor necrosis factor α antibody infliximab could reduce cellularity by the induction of apoptosis in synovial tissue. ## Methods Twenty‐four rheumatoid arthritis patients with active disease were randomized to receiv